Replication was blocked, went Ing cells infected with HIV closing Well below pull apoptosis.17 Maeda and colleagues HIV proviral DNA tested in an HIV-positive 8E5 cell line by RT-PCR and found that ATRA reduced the burden of proviral DNA in the cell line a dose-dependent ngigen way. They also examined the effects of ATRA on HIV replication in primary Ren lymphocytes from three Smoothened Pathway patients with HIV. ATRA significantly reduced the viral replication and found that ATRA is a load cap Be hige therapeutic agents, not only in APL, but HIV infection itself.18 Arsenic trioxide arsenic trioxide is the treatment of choice for most patients with relapsed APL, achieving the complete remission in about 85% to 88% of patients.19 arsenic trioxide acts by inducing the differentiation of malignant promyelocytes at lower concentrations, w while the foreigners measurement of apoptosis as well concentrations.12 The drug efficacy in patients with newly diagnosed APL as induction therapy demonstrated, allowing a 83% CR in 86% of patients, and 20.21 in the consolidation, in which event-free survival without the addition ATO has improved significantly compared to treatment with ATRA and chemotherapy only.22 Recent studies, however, it noted that the use of ATO in patients with HIV potentially improve viral infectivity t. In 2001, Turelli and colleagues suggested that the recruitment of cytoplasmic PML proteins with early steps of virus replication was hampered, suggesting that these proteins By degrading, ATO k nnte Tats Chlich f Rdern HIV infection.23 This one investigation has led to accelerated Berthoux and colleagues that reversetranscriptase due to the stimulation.
ATO, the kinetics of HIV-1 infection in human T-cells and increased ht the number of cells before the HIV-1 provirus after a single round of infection. This was obtained Hte levels of steady-state HIV-1 cDNA best CONFIRMS when ATO was added after infection.24 None of the previously F Ll of APL in HIV reported with ATO as part of relapse. Sutton reported a relapse, and conclude Lich induced his death in a patient with ATRA in the absence of anthracycline treatment, with no adult Hnung the continuation of treatment after relapse.3 Given the potential effect on viral infectivity t, where the ATO for patients living with HIV, is taken into account, the concomitant administration of HAART to be a reflexion. The r The specific HAART in the management of the PLA is a fertile ground for exploration. There are no uniform guidelines on the initiation or Cidofovir continuation of HAART w During chemotherapy and decisions are usually individualized. Investigate the gr Th series of AML to the treatment of HIV, became a standard induction chemotherapy cytotoxicity t noted relatively well in the presence of HAART.2 HIV treatment as part of the PLA tolerated Is possible Consistent with this observation. HAART was used in 4 of 7 F Cases examined here, with specific notes note minimal interferences with standard induction therapy in particular cases.13, 14 in one of the patients there was no interruption of antiretroviral therapy in its course. Myelosuppression is a well-established adverse effect older of inhibitors of reverse transcriptase, In particular zidovudine and the treatment of cancer in patients with HIV.2, 25 Bower and cowo complicate.